Retrospective Study
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Apr 15, 2022; 14(4): 920-934
Published online Apr 15, 2022. doi: 10.4251/wjgo.v14.i4.920
Table 1 Characteristics of the individual patients
No.
Age (yr)
Sex
ECOG PS
Primary tumor
Site of metastases
Liver metastases
RAS and BRAF mutation
Lines of treatment
Prior 5-Fu
Prior platinum
Prior irinotecan
Prior bevacizumab
Prior cetuximab
Prior regorafenib
Prior PD-1
156Female1Sigmoid colonAbdominal metastasesNoWild-type3YesYesYesYesYesNoNo
262Female3Ascending colonMultiple metastasesYesNot tested4YesYesYesYesNoYesNo
351Female0RectumMultiple metastasesYesNot tested3YesYesYesYesNoNoNo
452Female1Sigmoid colonMultiple metastasesNoKRAS mutation3YesYesYesYesNoNoNo
566Female1Ascending colonMultiple metastasesYesNot tested4YesYesYesYesNoYesNo
657Female2Sigmoid colonMultiple metastasesNoWild-type3YesYesYesYesYesNoNo
748Female3Liver curvature of the transverse colonMultiple metastasesYesNot tested3YesYesYesYesNoNoNo
861Female2RectumPelvic metastasesNoKRAS mutation3YesYesYesYesNoNoNo
965Female1RectumOvary metastasesNoWild-type4YesYesYesYesYesYesNo
1065Female0Ascending colonLung metastasesNoNot tested3YesYesYesYesNoNoNo
1156Female2Left half of the colonOvary metastasesNoWild-type3YesYesYesYesYesNoNo
1227Male0Sigmoid colonPelvic metastasesNoWild-type4YesYesYesYesYesYesYes
1358Male1Sigmoid colonLiver metastasesYesNot tested3YesYesYesYesNoNoNo
1470Female1RectumLung metastasesNoNot tested4YesYesYesYesNoNoNo
1554Male1Ascending colonMultiple metastasesYesKRAS mutation3YesYesYesYesNoNoNo
1655Male1RectumMultiple metastasesYesNRAS mutation4YesYesYesYesNoYesNo
1748Female0RectumMultiple metastasesYesWild-type3YesYesYesYesYesNoNo
1855Male1RectumMultiple metastasesYesWild-type3YesYesYesYesYesNoNo
1964Male2RectumMultiple metastasesYesKRAS mutation3YesYesYesYesNoNoNo
2058Female0Ascending colonMultiple metastasesYesWild-type3YesYesYesYesYesNoNo
2144Female2Sigmoid colonMultiple metastasesYesWild-type3YesYesYesYesYesNoNo
2251Male1RectumMultiple metastasesYesNot tested4YesYesYesYesNoYesNo
2356Male1RectumLung metastasesNoNot tested4YesYesYesYesNoNoNo
2461Male2RectumMultiple metastasesYesNot tested4YesYesYesYesNoNoNo
2573Male0RectumMultiple metastasesYes (radiofrequency)Wild-type3YesYesYesYesYesNoNo
2661Male1RectumMultiple metastasesYesWild-type4YesYesYesYesYesYesNo
2758Male2Sigmoid colonMultiple metastasesNoKRAS mutation3YesYesYesYesNoNoNo
2857Female1Sigmoid colonLiver metastasesYes (hepatectomy)KRAS mutation3YesYesYesYesNoNoNo
2967Male2RectumLiver metastasesYesNot tested3YesYesYesYesNoNoNo
3061Male1Sigmoid colonPeritoneal metastasisNoWide-type3YesYesYesYesYesNoNo
Table 2 Treatments and outcomes
No.
Initial dose of regorafenib (mg)
Dose adjustment (mg)
PD-1 inhibitor used in combination
Number of treatment cycles
Best response
PFS (mo)
OS (mo)
1120Camrelizumab16SD11.212.0
280Tislelizumab7SD5.07.0
3160160→80Nivolumab4PD3.4Not reached
480Camrelizumab4PD3.44.0
580Tislelizumab3SD2.05.0
680Toripalimab5SD3.5Not reached
780Tislelizumab7SD5.09.0
880Pembrolizumab5PD3.5Not reached
9120Sintilimab4SD2.8Not reached
10160160→80Toripalimab8SD5.6Not reached
1180Tislelizumab2SD1.4Not reached
12160Toripalimab4SD2.8Not reached
13120Nivolumab6SD4.2Not reached
1480Toripalimab5SD3.5Not reached
15120Sintilimab6SD3.5Not reached
1680Nivolumab15SD10.5Not reached
17160160→80Sintilimab4PD2.8Not reached
1880Camrelizumab5PD3.5Not reached
1980Toripalimab2SD1.4Not reached
20120Camrelizumab4PD3.47.0
2180Toripalimab2PD1.4Not reached
22120Camrelizumab1SD0.712.0
2380Sintilimab2PD1.410.0
2480Toripalimab9SD6.311.0
25120120→80Sintilimab2PD1.4Not reached
2680Sintilimab3SD2.110.0
2780Toripalimab6SD4.2Not reached
28120Sintilimab2PD1.4Not reached
2980Sintilimab1PD0.7not reached
3080Sintilimab2PD1.4Not reached
Table 3 Treatment-related adverse event
Adverse event
Number of patients (n = 30), n (%)

Any grade
Grade 1-2
Grade 3
Any event17 (56.7)13 (43.3)4 (13.3)
Hand-foot syndrome10 (33.3)8 (26.7)2 (6.7)
Hypertension 7 (23.3)7 (23.3)0
Malaise6 (20.0)6 (20.0)0
Gastrointestinal reaction5 (16.7)5 (16.7)0
Transaminase elevation4 (13.3)3 (10.0)1 (3.3)
Diarrhea 3 (10.0)3 (10.0)0
Abnormal capillary proliferation2 (6.7)1 (3.3)1 (3.3)
Hypothyroidism 2 (6.7)2 (6.7)0
Proteinuria 2 (6.7)2 (6.7)0
Rash2 (6.7)2 (6.7)0
Thrombocytopenia2 (6.7)2 (6.7)0
Anemia 1 (3.3)1 (3.3)0
Myocardial enzyme elevation1 (3.3)1 (3.3)0
Oral mucositis1 (3.3)1 (3.3)0
Leukopenia/neutropenia000